| titleOfInvention |
Polypeptide, non-peptide or not exclusively peptide compound, nucleotide sequence, process of preparing a polypeptide and demonstrating or isolating compounds capable of inhibiting, at least in part, the interaction between a preseniline and the precursor of the beta-amyloid peptide and / or the beta-amyloid peptide, host cell, tests for interaction between a presenilin and the precursor of the beta-amyloid peptide and / or the beta-amyloid peptide and for checking molecules capable of inhibiting the interaction between a presenilin and the precursor of the beta-amyloid peptide and / or beta-amyloid peptide, ligand, defective recombinant virus, vector, pharmaceutical composition, use of polypeptides and nucleotide sequence and expression cassette |
| abstract |
"POLYPEPTIDE, COMPOUND NON-PEPTIDE OR NON-EXCLUSIVELY PEPTIDE, NUCLEOTHYDICAL SEQUENCE, PROCESS OF PREPARING A POLYPEPTIDE AND DEMONSTRATING OR ISOLATING COMPOUNDS CAPABLE OF INHIBITING, ATOROO ATOMO ATENO A PEACE OF MIND. AND / OR BETA-AMYLOID PEPTIDE, HOSTING CELL, INTERACTION TESTS BETWEEN A PRESENILINE AND THE PRECURSOR OF THE BETA-AMYLOID PEPTIDE AND / OR THE BETA-AMYLOID PEPTIDE AND VERIFICATION OF LABORATORY LABORATORY CHEMISTRY OF PEACEFUL PEOPLE OF BETA-AMYLOID PEPTIDE AND / OR BETA-AMYLOID PEPTIDE, BINDING, DEFECTIVE RECOMBINANT VIRUS, VECTOR, PHARMACEUTICAL COMPOSITION, USE OF POLYPETIDES AND NUCLEOTIDIC SEQUENCE AND CASSETTE OF EXPRESSION. The present invention relates to new peptide and nucleotide sequences, and their pharmaceutical use. More particularly, the present invention relates to new polypeptides capable of inhibiting, at least in part, the interaction between presenilin 1 or presenilin 2, on the one hand, and the ß-amyloid peptide precursor and / or the ß peptide. -amyloid, on the other hand. The present invention also relates to the development of in vitro tests for the demonstration of molecules and, in particular, small molecules capable of inhibiting this interaction. |